{"title":"Cenobamate for focal‐onset seizures in resistant epilepsy","authors":"S. Chaplin","doi":"10.1002/psb.2018","DOIUrl":null,"url":null,"abstract":"Cenobamate (Ontozry) is a new antiseizure medicine for the adjunctive treatment of focal‐onset seizures with or without secondary generalisation in patients with drug‐resistant epilepsy. This article summarises its properties and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"153 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Cenobamate (Ontozry) is a new antiseizure medicine for the adjunctive treatment of focal‐onset seizures with or without secondary generalisation in patients with drug‐resistant epilepsy. This article summarises its properties and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
